news
Collaboration to produce new clinical stage TB drug candidates
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a CETR grant for tuberculosis drug development.
List view / Grid view
investment
news
$100 million is to be invested to increase vaccine manufacturing in US
A $100 million investment has been made to support long-term vaccine manufacturing capabilities in the US.
news
UK biotech funding increased by 85 percent in 2018
UK-based biotech companies raised £2.2billion from investors in 2018, an increase of 85 percent from the year before, a report has found...
news
NIAID plan for in-depth tuberculosis research
NIAID has released a plan for research in the infectious disease TB in order to strengthen efforts and resolve to attack this disease...
article
Servier: Bringing innovation to patients
Two years ago, Servier launched an ambitious programme of transformation to adapt to the new reality of the pharmaceutical industry. Olivier Laureau, CEO of Servier and President of the Fondation Internationale de Recherche Servier, explains the initiative and other achievements.
news
Brexit Health Alliance welcomes collaborative EU relationship
Niall Dickson responds to the commitment by the secretaries of state to seek a collaborative relationship with the EU in medicines regulation and supply...
news
NICE approves 3 drugs for treating plaque psoriasis in children
NICE has approved adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer) and ustekinumab (Stelara, Janssen) for treating plaque psoriasis in children...
news
Collaboration is ‘game changer’ in delivering cell and gene therapies
Collaboration between the pharmaceutical industry, patients and health regulators will be a ‘game changer’ in delivering exciting new cell and gene therapies to treat conditions like cancer and vision loss.
news
FDA approves BioMarin’s manufacturing facility in Cork, Ireland
The FDA has approved BioMarin Pharmaceutical’s bulk biologics manufacturing plant, located in Cork, Ireland for production of the formulated bulk substance.
article
Understanding today’s drug pricing environment
In a healthcare world that experiences a plethora of high-cost new therapies coming to market in parallel with price increases for existing speciality drugs, pharmaceutical companies are having to move away from traditional pricing models that are largely based on demand and what the market will bear. At the same…
news
Sanofi makes huge investment in the future of biologics
19 April 2016 | By Mandy Parrett, Editorial Assistant
Sanofi has announced plans to invest €300 million to expand its manufacturing and commercial capabilities at its site in Geel, Belgium.
